Epidemiology, Survival, and Clinical Characteristics of Inclusion Body Myositis
Ann Neurol 92:201-212, Lindgren, U.,et al, 2022
Inflammatory Myopathies with Anti-Ku Antibodies
Medicine 91:95-102, Rigolet,A.,et al, 2012
Disease Progression in Sporadic Inclusion Body Myositis: Observations in 78 Patients
Neurol 55:296-198, Peng,A. et al, 2000
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Weak at the Knees
Lancet 354:1696, Webster,G.&Beynon,H., 1999
Intravenous Immunoglobulin Treatment of Neurological Disease
JNNP 60:359-361, Otten,A.,et al, 1996
Investigation of Muscle Disease
JNNP 60:256-274, Mastaglia,F.L.&Laing,N.G., 1996
Common Variable Immunodeficiency and Inclusion Body Myositis:A Distinct Myopathy Mediated by Natural Killer Cells
Ann Neurol 37:806-810, Dalakas,M.C.&Illa,I., 1995
Neurologic Manifestations of Progressive Systemic Sclerosis
Arch Neurol 49:1292-1295, Averbuch-Heller,L.,et al, 1992
Polymyositis, Dermatomyositis, and Inclusion-Body Myositis
NEJM 325:1487-1498, Dalakas,M.C., 1991
Current Concepts in the Idiopathic Inflammatory Myopathies:Polymyositis, Dermatomyositis, and Related Disorders
Ann Int Med 111:143-157, Plotz,P.H.,et al, 1989
The Spectrum of Neurol Dis Assoc with Antiphospholipid Antibd, Lupus Anticoag & Anticardiolipin Antibd
Arch Neurol 44:876-883, Levin,S.R.&Welch,K.M.A., 1987
Inflammatory Myopathies
Ann Neurol 17:215-227, 317-3231985., Mastaglia,F.L.,et al, 1985